# Pteryxin enhances human NK-cell cytotoxicity by upregulating NKp30, NKp46, and 2B4 via ERK/AKT signaling

**Authors:** Eun Sun Park, Jong-Tae Kim, Yo-Sep Hwang, Jahyeong Han, Hyo-Min Park, Hyang Ran Yoon, Hee Jun Cho, Hee Gu Lee

PMC · DOI: 10.3389/fphar.2025.1698826 · Frontiers in Pharmacology · 2026-01-21

## TL;DR

Pteryxin boosts the ability of human NK cells to kill cancer cells by activating key signaling pathways and increasing the expression of important receptors.

## Contribution

Pteryxin enhances NK cell cytotoxicity via ERK/AKT signaling and upregulation of NKp30, NKp46, and 2B4.

## Key findings

- Pteryxin increases NK cell cytotoxicity against leukemia and colorectal cancer cells.
- Pteryxin activates ERK and AKT pathways, leading to higher granzyme B and perforin production.
- In mice, pteryxin reduces tumor growth, and this effect is blocked when NK cells are inhibited.

## Abstract

Natural killer (NK) cells play critical roles as effector cells by directly identifying and killing virus-infected and cancer cells. Pteryxin exhibits diverse antioxidant and anti-inflammatory effects; despite its known properties, the influence of pteryxin on NK cells is not understood fully. In this study, we evaluated the potential of pteryxin to enhance the cytotoxicity of NK cells. Pteryxin markedly enhanced the cytotoxic activities of both NK-92 and primary human NK cells against leukemia and colorectal cancer cell lines in a dose-dependent manner. Furthermore, it elevated the surface expression of key activating receptors NKp30, NKp46, and 2B4 in the NK-92 cells. This upregulation was accompanied by activation of the ERK and AKT signaling pathways, leading to increased production of cytotoxic mediators, including granzyme B and perforin. Moreover, in vivo studies using the CT26 mouse model revealed that pteryxin administration inhibited tumor growth in a dose-dependent manner. NK cells from the pteryxin-treated mice demonstrated enhanced cytotoxicity against YAC-1 leukemia cells. The anticancer effects of pteryxin were abolished when the NK cells were significantly reduced using anti-asGM1 antibody, confirming the critical role of the NK cells in its antitumor activity. Collectively, these findings demonstrate that pteryxin stimulates the ERK and AKT signaling pathways to enhance NK cell cytotoxicity against tumors, supporting its potential as a novel enhancer of NK-cell-driven antitumor responses.

## Linked entities

- **Proteins:** NCR3 (natural cytotoxicity triggering receptor 3), NCR1 (natural cytotoxicity triggering receptor 1), CD244 (CD244 molecule), PRF1 (perforin 1), EPHB2 (EPH receptor B2), AKT1 (AKT serine/threonine kinase 1)
- **Chemicals:** Pteryxin (PubChem CID 72431)
- **Diseases:** leukemia (MONDO:0004355), colorectal cancer (MONDO:0005575)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** NCR1 (natural cytotoxicity triggering receptor 1) [NCBI Gene 9437] {aka CD335, LY94, NK-p46, NKP46}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CD244 (CD244 molecule) [NCBI Gene 51744] {aka 2B4, NAIL, NKR2B4, Nmrk, SLAMF4}, GZMB (granzyme B) [NCBI Gene 3002] {aka C11, CCPI, CGL-1, CGL1, CSP-B, CSPB}, NCR3 (natural cytotoxicity triggering receptor 3) [NCBI Gene 259197] {aka 1C7, CD337, LY117, MALS, NKp30}
- **Diseases:** inflammatory (MESH:D007249), colorectal cancer (MESH:D015179), leukemia (MESH:D007938), cancer (MESH:D009369)
- **Chemicals:** Pteryxin (MESH:C019546)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12868148/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12868148/full.md

## References

31 references — full list in the complete paper: https://tomesphere.com/paper/PMC12868148/full.md

---
Source: https://tomesphere.com/paper/PMC12868148